Business
Immune Therapeutics, Inc. Shareholder Update Letter
Immune Therapeutics, Inc. Shareholder Update Letter.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc. Shareholder Update Letter\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc. Shareholder Update Letter\nPR Newswire\nORLANDO, Fla., Nov. 30, 2017\n\n\n\nORLANDO, Fla., Nov. 30, 2017 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB: IMUN), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products to alleviate human suffering in HIV/AIDS, cancer, pain, opportunistic infections and autoimmune and inflammatory disease areas today provided the following letter to shareholders: \n\nDear Shareholder:\n\nWe have had a lot of developments since our last Shareholder update. We know many of you have been asking for updates and we are excited to share the most recent news. We apologize for being relatively quiet this past year, but we will now make it a priority to have consistent updates for our shareholders. \n\nWe know results will speak for themselves and we have certainly had our challenges, but I am extremely excited and optimistic about our future.  Creating and developing the assets that we currently have has taken a considerable amount of time, dedication, effort and a \"never give-up\" attitude.  With many pieces of the puzzle now together, I believe that we are poised to embark on a journey that will transform Immune Therapeutics and propel us to success.\n\nWe are laying the foundation to support a company that we believe has the potential to generate significant revenues, profits, shareholder value, and most importantly a healthy future generation world wide.  In both the specialty pharmaceutical and biotechnology areas, we have a platform technology with a clear business model in place to optimize success. In order to achieve this success, we are now in the process of bringing in an experienced management team.  We have significant intellectual property, and very large potential markets for our product candidates.\n\nNigeria \n\nThe lack of revenue from Nigeria after obtaining approval has been major concern to shar...